You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
国药集团中国生物研发新冠灭活疫苗即将开始国际临床三期研究
阿思达克 06-24 07:36
国药集团中国生物宣布,其研发的新冠灭活疫苗即将在阿联酋开始国际临床三期研究,标志着全球首个新冠灭活疫苗国际临床试验正式启动。

国家科技部、国家卫健委早前通报,内地科研攻关团队按照灭活疫苗、基因工程重组亚单位疫苗、腺病毒载体疫苗、减毒流感病毒载体疫苗和核酸疫苗等5条技术路线,共布局12项疫苗研发任务。

目前,已对1个腺病毒载体疫苗、1个重组亚单位新冠疫苗、4个灭活疫苗开展临床试验,约占全世界开展临床试验疫苗总数的四成。

除国药集团外,康希诺与陈薇院士团队研发的新冠病毒疫苗已经在加拿大卫生部获批开展临床试验;北京科兴也与巴西生物研究机构宣布合作开展临床三期试验。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account